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Abstract: 
Depressive symptoms and episodes dominate the course of bipolar 
disorder. However, the therapeutic armamentarium for bipolar 
depression is limited.  Recent evidence points at the efficacy of 
second generation antipsychotics (SGAs) for the treatment of 
bipolar depression.  
We conducted a systematic review and meta-analysis of the 
efficacy and safety of SGAs (randomized, double-blind, placebo-
controlled trials; used in monotherapy) in the treatment of adult 
patients with bipolar depression. Publication bias was corrected for 
by performing similar searches using the clinical trials register of 
the respective pharmaceutical companies, the Cochrane database 
and ClinicalTrials.gov. Seven published papers were identified on 
the use of aripiprazole, olanzapine and quetiapine.  
Internal validity of the trials was fairly good, external validity only 




assessed.   When the individual trials were looked at, quetiapine 
and to a lesser extent olanzapine demonstrated significant 
improvement in MADRS total scores. This was not demonstrated for 
aripiprazole. Efficacy was hampered by adverse events, such as 
weight gain, akathisia, somnolence/sedation.  
Both clinical heterogeneity of the included trials and statistical 
heterogeneity of the meta-analytic data were considerable. The 
number of quetiapine trials was disproportionate versus the number 
of trials of aripiprazole and olanzapine. Further research is needed 
to assess differential efficacy of the different SGAs and their use in 
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Depressive symptoms and episodes dominate the course of bipolar disorder. However, the 
therapeutic armamentarium for bipolar depression is limited.  Recent evidence points at the efficacy 
of second generation antipsychotics (SGAs) for the treatment of bipolar depression.  
We conducted a systematic review and meta-analysis of the efficacy and safety of SGAs (randomized, 
double-blind, placebo-controlled trials; used in monotherapy) in the treatment of adult patients with 
bipolar depression. Publication bias was corrected for by performing similar searches using the 
clinical trials register of the respective pharmaceutical companies, the Cochrane database and 
ClinicalTrials.gov. Seven published papers were identified on the use of aripiprazole, olanzapine and 
quetiapine.  
Internal validity of the trials was fairly good, external validity only moderate. Different outcome 
measures of efficacy and safety were assessed.   When the individual trials were looked at, 
quetiapine and to a lesser extent olanzapine demonstrated significant improvement in MADRS total 
scores. This was not demonstrated for aripiprazole. Efficacy was hampered by adverse events, such 
as weight gain, akathisia, somnolence/sedation.  
Both clinical heterogeneity of the included trials and statistical heterogeneity of the meta-analytic 
data were considerable. The number of quetiapine trials was disproportionate versus the number of 
trials of aripiprazole and olanzapine. Further research is needed to assess differential efficacy of the 
different SGAs and their use in clinical practice.  
 
Keywords: second generation antipsychotics, placebo, depressive episode, bipolar disorder, meta-
analysis 





































































Bipolar disorder is a prevalent disorder, with poor symptomatic and psychosocial outcome (De Fruyt 
& Demyttenaere, 2007).  About half of the time, bipolar patients are symptomatically ill, with pure 
depressive symptoms predominating over manic, hypomanic or mixed symptoms (Judd et al., 2003; 
Judd et al., 2002). Some recent trends in the acute treatment of bipolar depression can be identified. 
Firstly, the importance of adequate mood stabilization is highlighted even in the acute treatment 
phase (De Fruyt & Demyttenaere, 2007). Secondly, the use of antidepressants is questioned due to 
their lack of efficacy, risk of induction of mania and cycle acceleration (Ghaemi et al., 2003; El-
Mallakh et al., 2007). Thirdly, second generation antipsychotics (SGAs) are being put forward 
(Calabrese et al., 2005a; Keck, Jr., 2005; Cousins & Young, 2007). This last trend seems to be in line 
with their proven efficacy in the acute treatment of mania and recent evidence of their prophylactic 
efficacy (Scherk et al., 2007; Sienaert & De Fruyt, 2007). This trend is also reflected in current clinical 
practice guidelines (Yatham et al., 2009).  
However, systematic reviews and meta-analyses addressing the efficacy/effectiveness of SGAs in 
acute bipolar depression are lacking. Two meta-analyses briefly discussed the efficacy and 
safety/acceptability of olanzapine and quetiapine monotherapy; more recent data on aripiprazole 
were not included (Derry & Moore, 2007; Van Lieshout & MacQueen, 2010). In another meta-
analysis (Cruz et al., 2009), aripiprazole data were included but only efficacy data were analyzed. 
Therefore, the aim of this paper was to compare the efficacy and safety of SGAs versus placebo, 
when used in monotherapy for the treatment of bipolar depression.  






































































We performed a Medline search. We made a selection for Randomized Controlled Trial (RCT) as 
article type. The titles and abstracts of articles were searched for: “Bipolar disorder” (MeSH term, 
search restricted to major topic headings only) AND (depression OR depressive) AND (amisulpride OR 
aripiprazole OR clozapine OR olanzapine OR paliperidone OR quetiapine OR risperidone OR 
ziprasidone OR zotepine). In addition, we hand searched the references of retrieved papers and key 
reviews. We identified the corresponding clinical study summaries of the finally selected papers at 
the clinical trials register of the respective pharmaceutical companies.  
For the selected SGAs (for which RCTs were found in the initial Medline search), we performed a 
similar search using the Cochrane Central Register of Controlled Trials (CENTRAL) database and 
ClinicalTrials.gov (http://clinicaltrials.gov). The clinical trials register of the respective pharmaceutical 
companies were finally checked to further identify trials that were not (yet) published.  
 
Selection  
In order to be included, trials had to be randomized, double-blind, placebo-controlled, and use a SGA 
in monotherapy to treat adult patients with documented bipolar disorder and a current depressive 
episode. Only papers with primary data analysis were withheld. Title and/or abstracts of selected 
papers were read, potentially useful reports were retrieved in full copy for final selection. Decisions 
on inclusion or exclusion were made by consensus.  
 
Validity assessment  




































































Two of the authors (ED & JDF) independently assessed the quality of the finally selected randomized 
controlled trials (RCTs) using the method described by Jadad et al. (Jadad et al., 1996): assessment of 
randomization, double blinding and description of withdrawals/dropouts, yielding a minimum score 
of 0 points and a maximum score of 5 points.  
 
Data abstraction  
Two of the authors (ED & JDF) independently extracted the data from the trials. Any disagreement 
was discussed and decisions were documented. The primary source of data were the published 
papers of the finally selected RCTs. When data were missing or RCTs were not published yet, the 
clinical study summaries were used.  
 
Quantitative data synthesis  
The primary outcome of interest was the mean change in Montgomery-Åsberg Depression Rating 
Scale (Montgomery & Asberg, 1979) (MADRS) score from baseline to endpoint. Secondary outcome 
measures were rates of response, remission, and dropout (due to any cause, lack of efficacy, adverse 
events), treatment emergent mania, mean weight gain, clinically significant weight gain, 
somnolence/sedation/fatigue,  akathisia and extrapyramidal symptoms (EPS).  
Efficacy and safety outcomes were combined. For continuous data, a weighted mean difference 
(WMD) was used as overall measure of treatment effect: this allows for direct interpretation by 
readers in common units used in the analyzed studies. Inverse variance weighting was used for 
pooling.  Therefore, the mean values and standard deviations of the continuous outcomes, and the 
number of participants were extracted. When standard deviations were not reported, they were 




































































derived from p values and confidence intervals, or the mean standard deviations of the other studies 
were used.  
For dichotomous outcome data, the relative risk (RR) was estimated, along with its 95% confidence 
interval (CI). Relative risks, rather than odds ratios, were chosen since they are intuitively better 
understood by physicians. The RR is normally defined as the risk of an unfavorable event in the 
intervention group divided by the risk of this event in the control group. Exceptions were made for 
the response and remission rate, where RR was calculated as the risk of a favorable event in the 
intervention group divided by the risk of this event in the control group. When treatment was 
significantly better than control, the number of participants needed to treat (NNT) was reported. 
NNT is calculated as the reciprocal of the risk difference (RD). Its 95% CI limits are derived as the 
inverse of the upper and lower limits of the 95% CI of the RD. NNT was rounded up to the next whole 
number. In case of a negative NNT (i.e. mor  good events with control than with treatment), the NNT 
is called the number of participants needed to harm (NNH). NNH was rounded up to the previous 
whole number.  
The DerSimonian-Laird random-effects model was used in all cases, even if heterogeneity was not 
statistically significant. Random-effects models are, in general, more conservative than fixed-effects 
models because they take heterogeneity among studies into account. Heterogeneity was determined 
by a χ2 test, contrasting the RR of the individual trials with the pooled RR. Because statistical tests of 
heterogeneity have low power, a significance level of 0.1 was used (Petitti, 2001).  
The results for continuous outcome measures are visualized in a forest plot, which shows the 
confidence interval for each individual study by a horizontal line. The corresponding point estimate is 
given by a square whose height is inversely proportional to the standard error of the estimate. The 
statistical analysis was carried out using R, free software available at http://www.r-project.org 
(version 2.8.0). Figures and results for the random-effects (DerSimonian-Laird) meta-analyses were 




































































produced in R using the rmeta (Thomas Lumley 2008, Version 2.14) and the meta (Guido Schwarzer 
2008, Version 0.9-17) library.  





































































Trial flow  
A first Medline search was performed on August 6, 2008, and yielded 57 papers, seventeen of which 
reported on the use of a SGA in patients with bipolar depression. One paper (Corya et al., 2006) was 
an open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy. In 
one paper (Shelton & Stahl, 2004) patients were randomized to risperidone, paroxetine or 
risperidone-paroxetine combination, added to a mood stabilizer. In one paper (Nierenberg et al., 
2006) patients were rand mly assigned to open-label adjunctive treatment with risperidone, 
lamotrigine or inositol. In one paper (Brown et al., 2006) patients were randomized to olanzapine-
fluoxetine combination or lamotrigine. Eight papers (Vieta et al., 2007; Tohen et al., 2007; Cookson et 
al., 2007; Endicott et al., 2007; Hirschfeld et al., 2006; Williamson et al., 2006; Keck, Jr. et al., 2005; 
Shi et al., 2004) were secondary analyses. No additional papers were found when the references of 
retrieved papers and key reviews were looked at. While preparing this manuscript, Medline searches 
were regularly updated. A final update was performed on December 16, 2009, and yielded 73 papers. 
No new RCTs were withheld.  
So, only five papers (Thase et al., 2006; Calabrese et al., 2005b; Tohen et al., 2003; Amsterdam & 
Shults, 2005; Thase et al., 2008) fulfilled the aforementioned selection criteria. In the paper of 
Amsterdam & Shults (Amsterdam & Shults, 2005) patients were randomized to treatment with 
fluoxetine, olanzapine, olanzapine-fluoxetine combination or placebo. Only nine patients were 
allocated to treatment with olanzapine: a small sample size in absolute numbers and relative to the 
other included trials. Furthermore, this paper reported efficacy in box plot figures, without providing 
actual numeric data. Therefore, this trial  was excluded from the meta-analysis. The clinical study 
summaries of the four remaining papers were identified at the respective clinical trials registers: 
aripiprazole trials CN138096 and CN138146 (Thase et al., 2008) (Bristol-Myers Squibb, 
http://ctr.bms.com/ctd/results.do), olanzapine trial F1D-MC-HGGY  (Tohen et al., 2003) (Eli Lilly and 




































































Company, http://www.lillytrials.com) and quetiapine trials 5077US/0049 (Calabrese et al., 2005b) 
and D1447C00135 (Thase et al., 2006) (AstraZeneca, http://www.astrazenecaclinicaltrials.com).  
In the AstraZeneca clinical trials register three additional trials were found: D1447C00134, 
D1447C00001 and D144CC00002. While preparing the final version of this manuscript, data of these 
additional quetiapine trials were published: D1447C00134 (McElroy et al., 2010), D1447C00001 
(Young et al., 2010) and D144CC00002 (Suppes et al., 2010).  
No further trials were identified for aripiprazole, olanzapine and quetiapine in the respective clinical 
trials registers, CENTRAL database and ClinicalTrials.gov.  
In summary, we finally selected seven published papers, three of which were not published yet at the 
first phase of our searches and data analysis.  
 
Study characteristics  
Five papers (Calabrese et al., 2005b; Thase et al., 2006; Young et al., 2010; McElroy et al., 2010; 
Suppes et al., 2010) reported on the use of quetiapine. In two of these trials patients were 
randomized to quetiapine (300 or 600 mg/day) or placebo (Calabrese et al., 2005b; Thase et al., 
2006). In one trial (McElroy et al., 2010) patients were randomized to quetiapine (300 or 600 
mg/day), paroxetine or placebo. In one trial (Young et al., 2010) patients were randomized to 
quetiapine (300 or 600 mg/day), lithium or placebo. In one trial (Suppes et al., 2010) patients were 
randomized to quetiapine sustained-release (300 mg/day) or placebo. This resulted in 5 trial arms of 
quetiapine 300mg/day and 4 trial arms of quetiapine 600mg/day. One paper (Tohen et al., 2003) 
reported on the use of olanzapine (5 to 20mg/day). One paper (Thase et al., 2008) reported on two 
trials of aripiprazole (5 to 30 mg/day).  




































































Overall, 2610 patients were randomized to SGAs, 1501 patients to placebo. The mean change in 
MADRS score from baseline to week 8 was the primary efficacy measure in all studies. Assessments 
were done weekly in three quetiapine trials (Calabrese et al., 2005b; Thase et al., 2006; Suppes et al., 
2010) and the aripiprazole trials (Thase et al., 2008). In two quetiapine trials (Young et al., 2010; 
McElroy et al., 2010), assessments were performed at baseline, weeks 1 and 2, and then every two 
weeks until week 8. In the olanzapine trial no assessments were done on week 5 and 7(Tohen et al., 
2003). Clinical and sociodemographic characteristics are summarized in Table 1. A more detailed 
description of selected patients (mainly based upon inclusion and exclusion criteria) is given in Table 
2.  
 
Validity assessment  
All trial reports scored 3 points or more when assessed by the method of Jadad et al. (Jadad et al., 
1996):  adequate reporting of randomization, double blinding and withdrawals/dropouts.   
 
Quantitative data synthesis  
Efficacy/effectiveness and safety data were analyzed for quetiapine, olanzapine and aripiprazole 
versus placebo, whenever comparable data were available. The authors decided to separate 
quetiapine 300 and 600mg. This decision was based upon the clinical profile with expected 
differences in efficacy and safety.  
 
Efficacy/effectiveness  




































































Figure 1. summarizes the results of the primary efficacy measure (MADRS mean change from 
baseline to endpoint).  
Table 3. summarizes the results of secondary efficacy/effectiveness measures: response, remission, 
dropout due to lack of efficacy and overall dropout. These dichotomous data are presented as RR 
and NNT/NNH.  
Subtle differences were found in the definition of response and remission. In all but one of the trials 
response was defined as ≥ 50% reduction from baseline to endpoint on the MADRS score. In the 
olanzapine trial (Tohen et al., 2003), response was defined as ≥ 50% reduction from baseline to 
endpoint on the MADRS score and completion of at least four weeks of study. In all the quetiapine 
trials (Calabrese et al., 2005b; Thase et al., 2006; Young et al., 2010; McElroy et al., 2010; Suppes et 
al., 2010), remission was defined as a MADRS score ≤ 12 at endpoint. In the olanzapine trial (Tohen et 
al., 2003), remission was defined as a MADRS score ≤ 12 at endpoint and completion of at least four 
weeks of study. In the aripiprazole trials (Thase et al., 2008), remission was defined as a MADRS score 
≤ 8 at endpoint.  
In all trials, drop-out due to “lack of efficacy” was described. Additional and overlapping causes of 
discontinuation were described: “condition under investigation worsened” (Suppes et al., 2010) and 
“relapsed to depression” (Tohen et al., 2003). Only data on “lack of efficacy” were used for analysis.  
 
Safety  
Figure 2. summarizes the results on weight gain.   
Table 4. summarizes the results of other safety measures: clinically significant weight gain (defined as 
≥ 7% increase from baseline to endpoint), EPS and akathisia, somnolence/sedation/fatigue, 




































































treatment emergent mania and dropout due to adverse events. These dichotomous data are 
presented as RR.  
The assessment of EPS and/or akathisia was heterogeneous across the trials. In all quetiapine trials, 
EPS and akathisia were assessed by the Simpson-Angus Rating Scale (SAS) and the Barnes Akathisia 
Rating Scale (BARS) (Calabrese et al., 2005b; Thase et al., 2006; Young et al., 2010; McElroy et al., 
2010; Suppes et al., 2010). In one trial (McElroy et al., 2010), an additional scale was used: the 
Abnormal Involuntary Movement Scale (AIMS). However, these quetiapine trials differed in the final 
reporting of rating scale scores: mean change in SAS from baseline (Calabrese et al., 2005b; Thase et 
al., 2006; Young et al., 2010), number of patients with an increase in SAS from baseline (Calabrese et 
al., 2005b; McElroy et al., 2010), mean change in BARS from baseline (Calabrese et al., 2005b; Young 
et al., 2010; McElroy et al., 2010), mean BARS score at last assessment (Thase et al., 2006), number 
of patients with an increase from baseline (Thase et al., 2006), number of patients with “no change” 
or “improvement” in SAS and BARS scores from baseline (Suppes et al., 2010). In all quetiapine trials 
the standardized assessments were supplemented by a mentioning of  adverse events “considered to 
be EPS” (Calabrese et al., 2005b; Thase et al., 2006) or adverse events “potentially associated with 
EPS” (Young et al., 2010; McElroy et al., 2010; Suppes et al., 2010). It was not always clear how this 
was assessed or conceptualized. In the Young et al. (Young et al., 2010) paper, adverse events 
“potentially associated with EPS” included the Medical Dictionary for Regulatory Activities (MedDRA) 
terms akathisia, hypokinesia, restlessness, tremor, dyskinesia, extrapyramidal disorder, psychomotor 
hyperactivity, hyperkinesia, hypertonia, muscle rigidity, and nuchal rigidity. In the McElroy et al. 
(McElroy et al., 2010) paper, adverse events “potentially associated with EPS” included the MedDRA 
terms akathisia, restlessness, tremor, dyskinesia, extrapyramidal disorder, dystonia, cogwheel 
rigidity, dyskinesia, hypokinesia and movement disorder. In the Suppes et al. (Suppes et al., 2010) 
paper, adverse events “potentially associated with EPS” included the MedDRA terms akathisia, 
dystonia, extrapyramidal disorder, hypertonia and tremor. In the Calabrese et al. (Calabrese et al., 




































































2005b) clinical trial report, rates of akathisia were reported, but these rates were not reported in the 
published paper. In the Thase et al. (Thase et al., 2006) clinical trial report, rates of “extrapyramidal 
disorder” were reported; these rates differed from the rates of adverse events “considered to be 
EPS” reported in the published paper.  
In the olanzapine trial (Tohen et al., 2003), EPS were assessed by the SAS and the AIMS. In the 
published paper, it was only reported that “the mean change in and emergence of EPS were low, 
with no statistical differences across treatment groups”. The percentage of patients who used 
anticholinergic medications at least once during the trial was also mentioned. In the clinical trial 
report, rates of treatment-emergent parkinsonism and dyskinesia were mentioned. These rates were 
based on the changes in SAS and AIMS.  
In the aripiprazole trials (Thase et al., 2006), EPS were assessed using the SAS, AIMS and BARS. 
Overall rates of “EPS-related adverse events” were reported, as well as more specific rates of 
akathisia and “EPS-related adverse events other than akathisia”. Also reported were changes from 
baseline to endpoint in SAS, AIMS and BARS score.  
In order to have a homogeneous assessment of EPS, only data for quetiapine (Calabrese et al., 
2005b; Thase et al., 2006; Young et al., 2010; McElroy et al., 2010; Suppes et al., 2010) and 
aripiprazole (Thase et al., 2008) could be used: “adverse events considered to be EPS”/“adverse 
events potentially associated with EPS” and “EPS-related adverse events” respectively. Likewise, in 
order to have a homogeneous assessment of akathisia, only limited data for quetiapine (Calabrese et 
al., 2005b) and aripiprazole (Thase et al., 2008) were used.  
In all trials,  somnolence/fatigue/asthenia/sedation were assessed. However, not all trials reported 
on all these different adverse events, nor was it stated how these overlapping adverse events were 
defined.  




































































In the quetiapine trials (Calabrese et al., 2005b; Thase et al., 2006; Young et al., 2010; McElroy et al., 
2010; Suppes et al., 2010) treatment-emergent mania was defined as a Young Mania Rating Scale 
score (YMRS) ≥ 16 on any two consecutive visits or at the final assessment, or an adverse event of 
mania or hypomania. In the olanzapine trial (Tohen et al., 2003), treatment-emergent mania was 
defined as a YMRS score of <  15 at baseline and ≥ 15 at any time thereafter. Treatment-emergent 
mania (with also data for mixed episodes) was unclearly defined in the aripiprazole trials (Thase et 
al., 2008). For aripiprazole combined data were used for mania and mixed episodes.  





































































This systematic review and meta-analysis studied the efficacy and safety of SGAs, used in 
monotherapy for the treatment of patients with bipolar depression. This paper  adds to previous 
meta-analyses by the inclusion of new reports on quetiapine and aripiprazole and the extensive 
assessment of both efficacy and safety. The authors have tried to minimize the problem of 
publication bias by not limiting the search to published papers (Medline) only; searches were also 
performed using the clinical trials register of the respective pharmaceutical companies, the Cochrane 
Central Register of Controlled Trials database and ClinicalTrials.gov.  
Seven papers were identified: one paper on the use of aripiprazole (two trials), one paper on the use 
of olanzapine and 5 papers on the use of quetiapine (five trial arms of quetiapine 300mg/day, four 
trial arms of quetiapine 600mg/day). All these trials were sponsored by the pharmaceutical industry. 
We could not identify any published reports on the use of amisulpride, clozapine, paliperidone, 
risperidone, ziprasidone or zotepine. For ziprasidone, two failed trials were found: not (yet) 
published when finalizing the manuscript. Overall, 4111 patients were included; 2610 patients were 
randomized to SGAs and 1501 to placebo. The average patient was middle aged, Caucasian, 
moderately depressed and treated in an outpatient setting.  
The absolute number of included trials was limited and the relative number of quetiapine trials 
versus trials of olanzapine and aripiprazole was disproportionate: a major limitation for meta-analytic 
purposes. However, the small number of included trials made it possible to have a closer look at 
different inclusion and exclusion criteria, subtle nuances in the assessment of efficacy and safety. 
These issues pertain to the external validity of RCTs and the meta-analytic merging of data that 
weren’t a priori produced for this purpose: issues that are often and inevitably overlooked in large 
scale meta-analyses.  




































































Internal validity of the included trials was fairly good as all trial reports scored ≥3 points, when 
assessed by the method of Jadad et al. (Jadad et al., 1996). External validity was only moderate, since 
information on recruitment procedure, treatment setting, duration of the current depressive 
episode, previous antidepressant treatment, previous treatment with mood stabilizers was limited to 
absent.  
When the individual trials were looked at, quetiapine (at both 300mg and 600mg) and to a lesser 
extent olanzapine demonstrated significant improvement in the MADRS total scores from baseline to 
endpoint: the primary efficacy endpoint.  This was not demonstrated for aripiprazole. Similar results 
were found for response and remission rates. Important side effects were as could be expected from 
former RCTs and clinical practice: weight gain (olanzapine, to a lesser extent quetiapine), akathisia 
(aripiprazole), somnolence (olanzapine and quetiapine 300 & 600mg), sedation (quetiapine 300 & 
600mg), low rates of EPS and fatigue. The results of weight gain should be interpreted with caution 
considering the short duration of the trials. As with schizophrenia, patients with bipolar disorder 
treated with SGAs have an increased risk for a metabolic syndrome (Newcomer, 2007; Correll et al., 
2008; Fagiolini et al., 2008); weight gain and other metabolic issues should be evaluated on the 
longer term. For those SGAs with proven efficacy, the NNH for somnolence/sedation were within the 
same range (or even lower) than the NNT for response and remission: a rather unfavourable 
risk/benefit ratio. However, interpretation of these findings should be done with caution, as only 
limited information is given on the persistence and severity of these side effects.  
When meta-analyzed, SGAs as a group were significantly better than placebo in four out of five 
outcome measures of efficacy:  WMD, response, remission and dropout due to inefficacy. Adverse 
events, significantly more associated with SGAs than with placebo, were (clinically significant) weight 
gain, EPS, akathisia, somnolence, sedation, fatigue and dropout due to adverse events. However, 
statistical heterogeneity (Q and corresponding p-value) was found for most efficacy and some safety 




































































measures: MADRS mean change from baseline to endpoint, remission, global dropout, inefficacy 
dropout, weight gain, clinically significant weight gain and somnolence.  
Besides the many different sources of clinical heterogeneity, as discussed below, differences in the 
studied drugs should be considered as the primary source of heterogeneity. Although SGAs are often 
considered as a group for meta-analysis (schizophrenia, mania and unipolar depression), SGAs are 
not alike and represent themselves an important source of heterogeneity (Scherk et al., 2007; 
Papakostas et al., 2007; Leucht et al., 2009). This seems  true when inspecting the forest plots for 
WMD (MADRS mean change from baseline to endpoint, weight gain) and the RRs (different efficacy 
and safety measures): e.g. non overlapping 95% CI for quetiapine (300 & 600mg) versus aripiprazole 
in MADRS score mean change from baseline, for (clinically significant) weight gain (olanzapine versus 
quetiapine 300 & 600mg and aripiprazole), global dropout (olanzapine versus aripiprazole). 
Interpretation of these results regarding differential efficacy and safety should be done with caution 
as the primary purpose of a meta-analysis still is the pooling and not the dissecting of data. 
Furthermore, for a better comparison of the different SGAs, more trials with olanzapine and 
aripiprazole are needed.  Duration of the trials was short and the question remains how the 
differential efficacy/effectiveness (SGAs versus placebo) evolves over time. In a subgroup of bipolar II 
patients treated with quetiapine, the change in MADRS score from baseline to endpoint was 
statistically superior to placebo at most assessments, but did not reach statistical significance at final 
assessment (Calabrese et al., 2005b). Likewise, statistical significance favouring aripiprazole was 
observed during weeks 1 to 6 (trial 1) and weeks 1 to 5 (trial 2) and was only lost during longer 
treatment (Thase et al., 2008). Another question, that could not be answered due to the nature of 
the studied trials (SGAs in monotherapy), was the differential efficacy (versus placebo) of SGAs when 
added to an ongoing treatment with a mood stabilizer. For antidepressants this differential efficacy is 
limited to absent (Sachs et al., 2007; Nemeroff et al., 2001).  




































































Direct evidence of clinical heterogeneity is found in the clinical samples (e.g. number of bipolar II 
patients, number of patients with a rapid cycling course), the large variation of baseline mean 
MADRS score (26.5 to 32.6), number of patient contacts. Bipolar II patients were only included in the 
quetiapine trials. One trial on quetiapine  found a lower efficacy in bipolar II than in bipolar I 
patients(Calabrese et al., 2005b). The advantage of antidepressant agents over placebo is higher in 
more severely depressed patients, as has been shown for antidepressants (Kirsch et al., 2008) and 
lamotrigine (Geddes et al., 2009). A higher number of patient contacts is associated with a higher 
therapeutic impact (Posternak & Zimmerman, 2007). Thereby, most of these differences are a 
potential source of heterogeneity.  
Heterogeneity is also found in the only partially overlapping definitions of efficacy/effectiveness and 
safety measures. This latter source of heterogeneity is avoidable and thereby a missed opportunity. 
Researchers should strive for a better consensus of the definition, use and reporting of outcome 
measures.  
Indirect evidence of heterogeneity is found in the large variation of placebo event rate for most 
efficacy measures: response (30 to 56%), remission (25 to 55%), global dropout (28 to 62%) and 
inefficacy dropout (5 to 32%). These differences are large for an identical placebo condition and 
could be explained by known (or unknown) clinical or methodological differences. The complexity of 
heterogeneity is further highlighted when comparing (visual inspection of the forest plot for MADRS 
mean change from baseline to endpoint; Figure 1) two quetiapine trials (Thase et al., 2006; Calabrese 
et al., 2005b) with identical study design: differences for efficacy were found to be higher between 
different studies (for same dose) than between different doses (for same study).  





































































This systematic review has found a considerable amount of data regarding the use of SGAs (in 
monotherapy) in patients with bipolar depression. Efficacy/effectiveness is found for quetiapine and 
to a lesser extent olanzapine. In a meta-analytic data analysis of this evidence, SGAs proved to have a 
superior efficacy versus placebo. However, clinical and statistical heterogeneity was high. An 
antidepressant ‘class effect’ of SGAs can’t be concluded. Side effects may hamper their clinical use: 
somnolence, sedation, akathisia, weight gain and other metabolic problems. Despite these 
limitations, SGAs like quetiapine and olanzapine have a place in the treatment of patients with 
bipolar depression, for whom treatment options are rather limited (until now mainly adequate mood 
stabilization, antidepressants and electroconvulsive therapy). Issues that certainly warrant further 
research are the impact of depression severity at baseline, the antidepressant efficacy/effectiveness 
beyond the acute phase, the efficacy/effectiveness when added to a mood stabilizer and the long 
term follow-up of side effects. This research and further clinical experience have to make clear which 
patients are most likely to benefit, which patients have the best risk/benefit ratio. SGAs (in particular 
quetiapine and olanzapine) have succeeded in their first ‘trial’ (i.e. RCTs and evidence based 
psychiatry) and should now be submitted to their second trial (i.e. careful application and evaluation 
in real life clinical practice) (Healy, 2009). This meta-analysis further highlights the important 
differences of SGAs: an overarching category of  compounds with different mechanisms of action and 
clinical usefulness.  
From a more methodological point of view, this review highlights how clinical trials are designed in 
an idiosyncratic way: unclear description of included patients, (subtle) differences in inclusion- and 
exclusion criteria, procedures, assessment of efficacy and safety, … The external validity of trials is 
thereby limited and individual trials are still difficult to compare.  
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Table 1. Demographic and clinical characteristics (part one)  
 
Intervention Dose, Mean (SD), Duration, Randomized, LOCF, Age, Mean Sex Race MADRS Completers, Source 
 [Range]  wk No. No. (SD), y Women, White, Score,   
      No. (%) No. (%) Mean (SD) No. (%)  
           
Quetiapine 600mg/day 8 180 170 37.3 (11.4) 99 (58.2) 144 (84.7) 30.3 (5.3) 98 (54.4) Calabrese et al., 2005 
Quetiapine 300mg/day 8 181 172 36.6 (11.2) 93 (54.1) 141 (82.0) 30.4 (5.0) 121 (66.9)  
Placebo  8 181 169 38.3 (11.1) 105 (62.1) 129 (76.3) 30.6 (5.3) 107 (59.1)  
           
Quetiapine 600mg/day 8 169 151 38.2 (11.0) 83 (55.0) 115 (76.2) 29.9 (5.6) 90 (53.3) Thase et al., 2006 
Quetiapine 300mg/day 8 172 155 37.2 (10.5) 86 (55.5) 107 (69.0) 31.1 (5.7) 101 (58.7)  
Placebo  8 168 161 37.7 (11.8) 97 (60.2) 138 (85.7) 29.6 (5.4) 110 (65.5)  
           
Quetiapine 600mg/day 8 268 263 42.8(11.4) 167 (63.5) 226 (85.9) 28.3 (6.5) 205 (76.5) Young et al., 2010 
Quetiapine 300mg/day 8 265 255 42.3 (11.7) 146 (57.3) 215 (84.3) 28.1 (6.2) 200 (75.5)  
Placebo  8 133 129 41.5 (12.7) 70 (54.3) 110 (85.3) 28.5 (6.1) 96 (72.2)  
           
Quetiapine 600mg/day 8 247 232 38.5 (11.3) 141(60.8) 132 (56.9) 26.5 (7.8) 159 (64.4)  McElroy et al., 2010 
Quetiapine 300mg/day 8 245 229 38.4 (11.0) 141(61.6) 134 (58.5) 27.1 (7.4) 160 (65.3)   
Placebo  8 126 121 38.7 (1.10) 81 (66.9) 72 (59.5) 27.2 (7.8) 76 (60.3)   
           
Quetiapine 300mg/day 8 140 133 39.0 (11.3) 88 (66.2) 96 (72.2) 29.8 (5.2) 87 (62.1) Suppes et al., 2010 
Placebo  8 140 137 39.9 (12.8) 86 (62.8) 98 (71.5) 30.1 (5.5) 96 (68.6)  
           
Olanzapine 9.7 mg/day [5 to 20 mg/day] 8 370 351 42.2 (12.5) 231 (62.4) 311 (84.1) 32.6 (5.8) 179 (48.4) Tohen et al., 2003 
Placebo  8 377 355 41.7 (12.4) 236 (62.6) 310 (82.2) 31.3 (5.8) 145 (38.5)  
           
Aripiprazole 17.6 (8.3) mg/day [5 to 30 mg/day] 8 186 164 39 (11) 115 (62) 164 (88) 29.07 99 (53.2) Thase et al., 2008 
Placebo  8 188 177 39 (13) 118 (63) 164 (87) 28.49 122 (64.9)  
           
Aripiprazole 15.5 (7.5) mg/day  [5 to 30 mg/day] 8 187 176 41 (12) 112 (60) 150 (80) 29.56 110 (58.8) Thase et al., 2008 




































































LOCF = last observation carried forward; MADRS = Montgomery-Åsberg Depression Rating Scale  
































































Table 2. Demographic and clinical characteristics (Part two)  
 
 Calabrese et al., 2005 Thase et al., 2006 McElroy et al., 2010 Young et al., 2010 Suppes et al., 2010 Tohen et al., 2003 Thase et al, 2008 
Age  18 to 65 years  18 to 65 years  18 to 65 years 18 to 65 years 18 to 65 years ≥ 18 years  18 to 65 years  
Out- versus 
inpatient  
Outpatients  Outpatients  -  Outpatients  Outpatients Mainly outpatients  
Inpatients: olanzapine 




Bipolar I disorder in 
majority of patients  
 






Bipolar I disorder in 
majority of patients  
 






Bipolar I disorder in 
majority of patients  
 






Bipolar I disorder in 
majority of patients  
 






Bipolar I disorder in 
majority of patients  
 
Bipolar II disorder:  
Quetiapine 300mg  
9.5%  
Placebo: 19.5% 




       
Severity  HDRS 17-item ≥ 20 
HDRS item 1 ≥ 2  







No current serious 
suicidal or homicidal 
risk 
HDRS 17-item ≥ 20 
HDRS item 1 ≥ 2  







No current serious 
suicidal or homicidal 
risk 
HDRS 17-item ≥ 20  








No HDRS item 3 
(suicide) ≥ 3 
HDRS 17-item ≥ 20  








No current serious 
suicidal or homicidal 
risk 
HDRS 17-item ≥ 20 
HDRS item 1 ≥ 2  







No current serious 
suicidal or homicidal 
risk, no HDRS item 3 
(suicide) ≥ 3, no 
attempted suicide 
within in the past 6 
months  
MADRS ≥ 20  








No suicidal behaviour 
within 3 months  
HDRS 17-item ≥ 18  
HDRS item 1 ≥ 2  
At both screening and 
randomization, with a 
≤ 25% decrease in 


















YMRS ≤ 12  at both 
screening  
and randomization  
 
 











worsening of manic 
symptoms (YMRS ≥ 15 
during weeks 1 to 3) 
were discontinued  
YMRS ≤ 12 
At both screening and 
randomization, with < 
4-point increase 
between those visits  

































































Mean YMRS score 
(SD):  
Quetiapine 600mg 4.8 
(3.2)  
Quetiapine 300mg 4.9 
(2.8)  
Placebo 4.9 (3.2)  
 
Mean YMRS score 
(SD):  
Quetiapine 600mg 5.4 
(2.79)  
Quetiapine 300mg 5.8 
(3.30)  
Placebo 5.8 (3.00)  
 
Mean YMRS score 
(SE):  
Quetiapine 600mg 5.9 
(0.21)  
Quetiapine 300mg 5.5 
(0.19)  
Placebo 5.9 (0.30) 
 
Mean YMRS score 
(SE):  
Quetiapine 600mg 3.3 
(0.12)  
Quetiapine 300mg 3.1 
(0.12)  
Placebo 3.3 (0.19) 
 
Mean YMRS score 
(SD):  
Olanzapine 5.0 (4.8)  
Placebo 4.8 (4.6)  
Psychotic 
features  
- - - - - Olanzapine 13.5% 
Placebo 12.7%  
No psychotic features  
Melancholic 
features  
-  -  - - - Olanzapine 66.5%, 




-  -  - - - Olanzapine 9.2% 
Placebo 7.7%  
-  
        
Duration  ≥ 4 weeks, ≤ 1 year   ≥ 4 weeks, ≤ 1 year   ≥ 4 weeks, ≤ 1 year   ≥ 4 weeks, ≤ 1 year   ≥ 4 weeks, ≤ 1 year 
 
Mean (SD)  duration 
of current depressive 
episode: 
Quetiapine 300mg 
19.3 (12.8) weeks  




Median length of 
current depressive 
episode:  
Olanzapine 63 days 
Placebo 82 days  
≥ 2 weeks, ≤ 2  years    
Treatment 
resistance  
No history of 
treatment 
nonresponse (i.e. an 
adequate trial of > 2 
classes of 
antidepressants)   
No history of 
treatment 
nonresponse (i.e. an 
adequate trial of > 2 
classes of 
antidepressants)   
- No history of 
treatment 
nonresponse (i.e. an 
adequate trial of ≥ 2 
classes of 
antidepressants)   
No history of 
treatment 
nonresponse (i.e. an 
adequate trial of > 2 
classes of 
antidepressants) 
-  No history of 
treatment 
nonresponse (i.e. an 















quetiapine or lithium  







Rapid cycling course is 
allowed, but no more 
Rapid cycling course is 
allowed, but no more 
Rapid cycling course is 
allowed, but no more 
A history of ≥ 1 
previous manic or 
No late onset 
depression  



































































































Placebo 32.9%  
than 8 episodes in the 

















than 8 episodes in the 

















than 8 episodes in the 















mixed episode of 
sufficient severity to 
require treatment 
with a mood stabilizer 
or an antipsychotic  
 
Manic or mixed 
episode in the last 12 
months:  
Olanzapine 83.5% 
Placebo 77.8%  
 
Rapid cycling course:  
Olanzapine 38.4%  
Placebo 35.0%  
 
No first depressive 
episode  
 
No ≥ 6 manic and/or 
major depressive 






Median ± SD number 
of mood episodes 
within past 12 
months: placebo 2.3 ± 
1.0, aripiprazole 2.4 ± 
1.0  
Comorbidity  No other axis I 
disorder as primary 
focus of treatment 

















substance use (except 
for nicotine) within 12 
months  
No other axis I 
disorder as primary 
focus of treatment 

















substance use (except 
for nicotine) within 12 
months  
No other axis I 
disorder as primary 
focus of treatment 

















substance use (except 
for nicotine) within 12 
months  
No other axis I 
disorder as primary 
focus of treatment 

















substance abuse  
 
 
No other axis I 
disorder as primary 
focus of treatment 











































No other primary 
psychiatric disorder 
with a major 







within 3 months  
 







dependence  (or 
abuse) within 6 (or 3) 
months  
 













































































No clinically relevant 










HDRS = Hamilton Depression Rating Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; YMRS = Young Mania Rating Scale  
































































Table 3. Efficacy/effectiveness measures: SGAs versus placebo  
 
Events/total patients 
(Event Rate (%)) 
 Trials 
Treatment Placebo 
RR (95% CI) NNT (95% CI) Heterogeneity 
Q (p-value) 
Pooled RR Effect Test 
z (p-value) 
Response         
Quetiapine 600 4 526/816 (64) 269/580 (46) 1.33 (1.19 ; 1.47) 7 (5 ; 10) 3.32 (0.345) 5.24 (<0.001) 
Quetiapine 300 5 607/944 (64) 328/717 (46) 1.36 (1.23 ; 1.49) 6 (5 ; 9) 4.47 (0.347) 6.12 (<0.001) 
Olanzapine 1 137/351 (39) 108/355 (30) 1.28 (1.05 ; 1.57) 12 (7 ; 63) . . 
Aripiprazole 2 148/337 (44) 147/353 (42) 1.05 (0.88 ; 1.25) NA 0.30 (0.582) 0.57 (0.569) 
All SGAs pooled 12 1418/2448 (58) 852/2005 (42) 1.3 (1.21 ; 1.39) 8 (7 ; 10) 14.75 (0.194) 7.28 (<0.001) 
        
Remission         
Quetiapine 600 4 513/816 (63) 246/580 (42) 1.39 (1.19 ; 1.63) 6 (5 ; 9) 6.50 (0.090) 4.06 (<0.001) 
Quetiapine 300 5 569/944 (60) 300/717 (42) 1.36 (1.18 ; 1.57) 7 (5 ; 10) 7.97 (0.093) 4.26 (<0.001) 
Olanzapine 1 115/351 (33) 87/355 (25) 1.34 (1.06 ; 1.69) 13 (7 ; 62) . . 
Aripiprazole 2 94/337 (28) 100/353 (28) 0.99 (0.78 ; 1.25) NA 0.73 (0.393) -0.11 (0.915 ) 
All SGAs pooled 12 1291/2448 (53) 733/2005 (37) 1.32 (1.2 ; 1.45) 9 (7 ; 11) 21.15 (0.032) 5.83 (<0.001) 
        
     NNH (95% CI)   
Global Dropout        
Quetiapine 600 4 312/864 (36) 219/608 (36) 1.05 (0.86 ; 1.29) NA 6.53 (0.088) 0.48 (0.632) 
Quetiapine 300 5 333/1002 (33) 261/746 (35) 0.98 (0.82 ; 1.16) NA 6.71 (0.152) -0.25 (0.806 ) 
Olanzapine 1 191/370 (52) 232/377 (62) 0.84 (0.74 ; 0.95) -11 (-36 ; -6) . . 
Aripiprazole 2 164/373 (44) 122/376 (32) 1.35 (1.13 ; 1.63) 8 (5 ; 21) 0.04 (0.846) 3.21 (0.001) 
All SGAs pooled 12 1000/2609 (38) 834/2107 (40) 1.04 (0.92 ; 1.18) NA 31.96 (0.001) 0.60 (0.549) 
        
Inefficacy Dropout        
Quetiapine 600 4 13/864 (2) 50/608 (8) 0.23 (0.1 ; 0.56) 16 (12 ; 25) 5.06 (0.168) -3.27 (0.001) 
































































Quetiapine 300 5 23/1002 (2) 60/746 (8) 0.3 (0.16 ; 0.56) 19 (14 ; 30 ) 5.96 (0.202) -3.71 (<0.001) 
Olanzapine 1 73/370 (20) 121/377 (32) 0.61 (0.48 ; 0.79) 9 ( 6 ; 17 ) . . 
Aripiprazole 2 16/373 (4) 27/376 (7) 0.6 (0.25 ; 1.42) NA 1.94 (0.163) -1.16 (0.247) 
All SGAs pooled 12 125/2609 (5) 258/2107 (12) 0.37 (0.25 ; 0.55) 16 ( 13 ; 21 ) 22.92 (0.018) -4.81 (<0.001) 
 
RR = relative risk; NNT =  number needed to treat; NNH = number needed to harm; SGAs = second generation antipsychotics  
































































Table 4. Safety measures: SGAs versus placebo  
 
Events/total patients 
(Event Rate (%)) 
 Trials 
Treatment Placebo 
RR (95% CI) NNH (95% CI) Heterogeneity 
Q (p-value) 
Pooled RR Effect Test 
z (p-value) 
Adverse Event Dropout        
Quetiapine 600 4 131/864 (15) 39/608 (6) 2.36 (1.34 ; 4.17) 10 (8 ; 16) 7.21 (0.066) 2.96 (0.003) 
Quetiapine 300 5 107/1002 (11) 41/746 (5) 2.05 (1.09 ; 3.86) 19 (12 ; 38) 10.84  (0.028) 2.22 (0.027) 
Olanzapine 1 34/370 (9) 19/377 (5) 1.82 (1.06 ; 3.14) 24 (12 ; 212) . . 
Aripiprazole 2 50/373 (13) 24/376 (6) 2.1 (1.32 ; 3.35) 14 (8 ; 35) 0.11 (0.744) 3.13 (0.002) 
All SGAs pooled 12 322/2609 (12) 123/2107 (6) 2.03 (1.53 ; 2.69) 15 (12 ; 20) 19.61 (0.051) 4.95 (<0.001) 
        
Somnolence        
Quetiapine 600 4 184/859 (21) 38/602 (6) 3.52 (2.24 ; 5.53) 6 (5 ; 7) 5.21 (0.157) 5.45 (<0.001) 
Quetiapine 300 5 233/990 (24) 46/742 (6) 3.91 (2.77 ; 5.53) 5 (4 ; 6) 5.1 (0.277) 7.73 (<0.001) 
Olanzapine 1 104/370 (28) 47/377 (12) 2.25 (1.65 ; 3.08) 6 (4 ; 10) . . 
Aripiprazole 2 27/360 (8) 15/367 (4) 1.83 (0.99 ; 3.38) NA 0.00 (0.949) 1.93 (0.054) 
All SGAs pooled 12 548/2579 (21) 146/2088 (7) 3.18 (2.48 ; 4.08) 6 (5 ; 7) 19.2 (0.058) 9.11 (<0.001) 
        
CS Weight gain        
Quetiapine 600 4 69/863 (8) 15/606 (2) 3.08 (1.77 ; 5.34) 18 (13 ; 31) 1.02 (0.797) 3.99 (<0.001) 
Quetiapine 300 5 56/970 (6) 16/731 (2) 2.37 (1.22 ; 4.59) 27 (18 ; 58) 5.36 (0.253) 2.55 (0.011) 
Olanzapine 1 65/347 (19) 1/355 (0) 66.5 (9.28 ; 476.57) 5 (4 ; 6) . . 
Aripiprazole 2 17/360 (5) 12/367 (3) 1.45 (0.7 ; 3.01) NA 0.57 (0.449) 1.00 (0.316) 
All SGAs pooled 12 207/2540 (8) 44/2059 (2) 2.77 (1.72 ; 4.45) 16 (13 ; 20) 20.34 (0.041) 4.21 (<0.001) 
        
Treatment Emergent Mania        
Quetiapine 600 4 26/863 (3) 30/606 (5) 0.57 (0.33 ; 0.98) -53 (-653 ; 26) 2.61 (0.455) -2.02 (0.044) 
Quetiapine 300 5 32/997 (3) 39/746 (5) 0.62 (0.26 ; 1.47) NA 10.32 (0.035) -1.09 (0.277) 
































































Olanzapine 1 19/335 (6) 23/345 (7) 0.85 (0.47 ; 1.53) NA . . 
Aripiprazole 2 11/360 (3) 6/367 (2) 1.88 (0.7 ; 5.03) NA 0.01 (0.937) 1.26 (0.208) 
All SGAs pooled 12 88/2555 (3) 98/2064 (5) 0.73 (0.48 ; 1.11) NA 18.45 (0.072) -1.48 (0.138) 
        
Fatigue        
Quetiapine 600 3 59/592 (10) 30/471 (6) 1.65 (1.08 ; 2.54) 23 (13 ; 113) 0.64 (0.726) 2.29 (0.022) 
Quetiapine 300 4 56/730 (8) 33/611 (5) 1.44 (0.94 ; 2.2) NA 1.76 (0.624) 1.68 (0.093) 
Olanzapine 1 36/370 (10) 12/377 (3) 3.06 (1.62 ; 5.78) 15 (9 ; 32) . . 
Aripiprazole 2 42/360 (12) 22/367 (6) 1.92 (1.17 ; 3.15) 17 (10 ; 65) 0.65 (0.422) 2.58 (0.010) 
All SGAs pooled 10 193/2052 (9) 97/1826 (5) 1.79 (1.41 ; 2.27) 22 (16 ; 36) 6.69 (0.641) 4.75 (<0.001) 
        
Sedation        
Quetiapine 600 4 157/859 (18) 36/602 (6) 3.5 (2.48 ; 4.95) 6 (5 ; 8) 2.76 (0.43)  7.12 (<0.001) 
Quetiapine 300 5 187/990 (19) 46/742 (6) 3.49 (2.57 ; 4.74) 6 (5 ; 8) 1.74 (0.784) 8.02 (<0.001) 
Aripiprazole 2 19/360 (5) 8/367 (2) 2.42 (1.07 ; 5.46) 32 (17 ; 289) 0.00 (0.946) 2.13 (0.033) 
All SGAs pooled 11 363/2209 (16) 90/1711 (5) 3.4 (2.73 ; 4.24) 7 (6 ; 9) 5.23 (0.875) 10.9 (<0.001) 
        
EPS        
Quetiapine 600 4 77/863 (9) 29/606 (5) 1.95 (0.95 ; 3.98) NA 7.7 (0.053) 1.83 (0.067) 
Quetiapine 300 5 72/997 (7) 30/746 (4) 1.93 (0.89 ; 4.16) NA 10.85 (0.028) 1.68 (0.094) 
Aripiprazole 2 115/360 (32) 37/367 (10) 3.16 (2.25 ; 4.45) 4 (3 ; 6) 0.42 (0.517) 6.62 (<0.001) 
All SGAs pooled 11 264/2220 (12) 96/1719 (6) 2.16 (1.44 ; 3.23) 14 ( 11 ; 18) 27 (0.003) 3.73 (<0.001) 
        
Akathisia        
Quetiapine 600 1 9/180 (5) 2/180 (1) NA NA . . 
Quetiapine 300 1 9/179 (5) 2/180 (1) NA NA . . 
Aripiprazole 2 88/360 (24) 16/367 (4) 5.59 ( 3.35 ; 9.33) 4 (3 ; 6) 0.19 (0.666) 6.59 (<0.001) 
All SGAs pooled 4 106/719 (15) 20/727 (3) 5.37 ( 3.38 ; 8.53) 8 (6 ; 10) 0.31 (0.958) 7.13 (<0.001) 
 
































































RR = relative risk; NNH = number needed to harm; SGAs = second generation antipsychotics  
 
































































Figure 1. MADRS mean change from baseline to endpoint: SGAs versus placebo  
 
MADRS = Montgomery-Åsberg Depression Rating Scale; WMD = weighted mean difference  
 
 
































































Figure 2. Weight gain from baseline to endpoint: SGAs versus placebo  
 
WMD = weighted mean difference  
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